Insulet Corporation Stock

$289.32

2.72% day before yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US45784P1012

Symbol

PODD

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Insulet Corporation Stock price

$289.32

+95.31 49.13% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-8.08 2.72%

ISIN

US45784P1012

Symbol

PODD

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$20.4b

Enterprise Value

$20.9b

Net debt

$539.6m

Cash

$1.2b

Shares outstanding

70.4m

Valuation (TTM | estimate)

P/E

53.4 | 65.5

P/S

9.3 | 7.9

EV/Sales

9.5 | 8.1

EV/FCF

74.4

P/B

15.3

Financial Health

Equity Ratio

39.2%

Return on Equity

34.5%

ROCE

11.4%

ROIC

Debt/Equity

1.3

Financials (TTM | estimate)

Revenue

$2.2b | $2.6b

EBITDA

$424.5m | $565.4m

EBIT

$340.8m | $424.9m

Net Income

$402.2m | $311.0m

Free Cash Flow

$280.8m

Growth (TTM | estimate)

Revenue

23.5% | 24.5%

EBITDA

31.2% | 45.1%

EBIT

36.8% | 37.5%

Net Income

71.9% | -25.7%

Free Cash Flow

105.4%

EPS

$5.4

FCF per Share

$4.0

Short interest

4.1%

Employees

Rev per Employee

$530.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Insulet Corporation Stock Analysis

Unlock Scores for Free

??

32 Analysts have issued a Insulet Corporation forecast:

27x Buy

84%

5x Hold

16%

More details on Analyst Estimates Including Price Targets

32 Analysts have issued a Insulet Corporation forecast:

Buy

84%

Hold

16%

Analyst Estimates with Stock Price Targets

Financial data from Insulet Corporation

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2,199 2,199	23% 23% 100%
- Direct Costs	651 651	17% 17% 30%
Gross Profit	1,548 1,548	26% 26% 70%
- Selling and Administrative Expenses	978 978	27% 27% 44%
- Research and Development Expense	229 229	12% 12% 10%
EBITDA	425 425	31% 31% 19%
- Depreciation and Amortization	84 84	13% 13% 4%
EBIT (Operating Income) EBIT	341 341	37% 37% 15%
Net Profit	402 402	72% 72% 18%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Insulet Corporation Stock News

Neutral

Business Wire

●

5 days ago

Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call...

Neutral

Investors Business Daily

●

12 days ago

Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids

Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech.

Positive

The Motley Fool

●

15 days ago

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

More Insulet Corporation News

Company Profile

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Head office	United States
CEO	Ashley McEvoy
Employees	3,900
Founded	2000
Website	www.omnipod.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now